Nymox Reports Positive Results From Combined Statistical Analysis of Long Term Follow-Up Studies of BPH Drug
HASBROUCK HEIGHTS, N.J., July 31, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported positive results from a new study of long-term treatment outcomes for men who had received a single injection of NX-1207 2.5 mg for treatment for their benign prostatic hyperplasia (BPH). The study analysis found that a statistically significant greater number of men who had received NX-1207 2.5 mg reported positive treatment outcomes as compared to men who had received a placebo. The study involved the latest available blinded follow-up study data (an average of 57 months post-injection) from the completed clinical trials for these treatment groups. A positive treatment outcome was seen if the patient was not using other BPH medications and no surgical treatment (including MIST) for BPH was reported at any time during the post-injection follow-up period.
The combined new statistical analysis of blinded study data
showed
NX-1207 2.5 mg to have a lasting benefit in terms of positive
treatment outcomes that was significantly superior to placebo
(p=.02). Previous follow-up studies have shown long-term benefit
from a single NX-1207 treatment in excess of 5 years in some
cases.
Nymox recently provided an update on the Company's Phase 3
pivotal trials for NX-1207. The Safety Monitoring Committee meeting
of July 12,
2012 was favorable and indicated no significant safety concerns for
the two pivotal U.S. trials to date. Patient recruitment and trial
activities for pivotal U.S. studies NX02-0017 and NX02-0018 are
nearing completion at over 70 well-known urology investigative
sites throughout the U.S.
NX-1207 has been found in previous studies to improve the signs
and symptoms of BPH, producing improvements which reached
statistical significance compared to double-blinded placebo and
study controls. A single administration of NX-1207 2.5 mg has
produced on average improvements in the standardized BPH symptom
score (8-10 points at 90
days) that were approximately double that reported for currently
approved BPH drugs (3-5 points). The drug is administered by a
urologist in an office setting and involves little or no pain or
discomfort. NX-1207 has not been found to have the sexual, blood
pressure, or other side effects of the approved drugs.
BPH is one of the most commonly diagnosed diseases in the male
U.S.
population. The condition can seriously impact the health and
quality of life of older men and can lead to acute urinary
retention, incontinence, and other serious consequences. It is
estimated that 50% of men in their 50s have pathological signs of
prostatic hyperplasia and from 26 to 46% of men between the ages of
40 to 79 years suffer from moderate to severe urinary problems and
symptoms associated with BPH.
More information about Nymox is available at www.nymox.com,
email:
info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Posted: August 2012
